Physician profile
Michael S Kellogg
NPI 1205879467
$18,571.45
in general payments reported to CMS, 2019-2025
73 companies · $2,913 in 2025
The $2,913 reported for 2025 was more than what 96% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,395 · 2020: $1,103 · 2021: $2,665 · 2022: $3,125 · 2023: $3,241 · 2024: $3,130 · 2025: $2,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,132 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,132.32 |
| Education | $151.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,281.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,892.55 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,860.00 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,480.44 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,234.71 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $1,155.03 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $854.95 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $792.01 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Astellas Pharma US INC | $691.16 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $603.90 | 2019-2025 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $302.04 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $263.62 | 2019-2023 | Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $224.54 | 2021-2025 | Rexulti |
| Esperion Therapeutics, INC. | $220.59 | 2020-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $211.03 | 2019-2023 | Trintellix |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kellogg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.